Immuno Delivery (Focus Group - ID)

(247) Development of mRNA nanoparticles to produce CAR - T cells to treat Diffuse Intrinsic Pontine Glioma

Introduction:

Diffuse Intrinsic Pontine Glioma (DIPG) is a fatal paediatric brain cancer located in the pons. Chimeric antigen receptor (CAR)-modified T cells engineered ex vivo show promise in suppressing brain tumours¹yet applicability in DIPG is hindered by off-target toxicities, high production cost and time. Overcoming these challenges, we propose utilizing advances in mRNA therapy and nanomedicine to generate CAR T cells directly in vivo. This approach aims to produce CAR T cells in a controlled and low-toxic manner thus overcoming the main disadvantages of conventional CAR-T cell therapy.

Learning Objectives:

Understand a novel in vivo CAR T generation approach
Evaluate the efficacy of LNP mediated CAR T cell transfection
Evaluate the translational potential of in vivo CAR T generation through pre-clinical studies

Poster Presenter(s)

Lakshika R K Waththage, n/a

Ms
Children's Cancer Institute, University of New South Wales
Sydney, New South Wales, Australia